Status:

COMPLETED

The Expression and Significance of MiRNA

Lead Sponsor:

Megan Ballinger

Conditions:

Pulmonary Arterial Hypertension

Eligibility:

All Genders

18+ years

Brief Summary

It is not always known what causes PAH or what the best treatment is. The doctors doing this study would like to understand more about why some people develop PAH and other do not. They also would lik...

Detailed Description

You will be asked to donate blood when you have your right heart catheterization and also at the 3-4 month follow-up visit. The amount of blood collected during your heart catheterization is about 20c...

Eligibility Criteria

Inclusion

  • ≥ 18 years of age
  • Not pregnant
  • Undergoing right heart catheterization for PAH diagnosis

Exclusion

  • Pregnant

Key Trial Info

Start Date :

July 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 16 2018

Estimated Enrollment :

207 Patients enrolled

Trial Details

Trial ID

NCT00806312

Start Date

July 1 2008

End Date

August 16 2018

Last Update

November 2 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Ohio State University

Columbus, Ohio, United States, 43210

The Expression and Significance of MiRNA | DecenTrialz